Daniel P. Petrylak, MD, Says Maintenance Immunotherapy Has Become Standard Practice in Bladder Cancer

Video

At the 15th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies, Daniel P. Petrylak, MD, spoke about how immunotherapy has influenced treatment for patients with bladder cancer.

CancerNetwork® spoke with Daniel P. Petrylak, MD, professor of medicine (medical oncology) and of urology and co-leader of Cancer Signaling Networks at Yale Cancer Center, about using maintenance immunotherapy as a standard of care for patients with bladder cancer. He spoke on the topic at the 15th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies, hosted by Physicians’ Education Resource®, LLC (PER®), for which he served as meeting co-chair.

Transcript:

Immunotherapy is now considered standard of care for patients who respond to frontline chemotherapy for metastatic urothelial carcinoma. By respond, I define that as stable, complete, or partial response to chemotherapy, which could be either cisplatin and gemcitabine, carboplatin and gemcitabine, or the MVAC regimen [which includes methotrexate, vinblastine sulfate, doxorubicin hydrochloride, and cisplatin]. There’s a significant improvement in survival in those patients who receive maintenance of avelumab [Bavencio] compared with those who receive just best standard of care in that setting. We view that as standard treatment for these patients.

Related Videos
Barbara Smith, MD, PhD, spoke about the potential use of pegulicianine-guided breast cancer surgery based on reports from the phase 3 INSITE trial.
Patient-reported symptoms following surgery appear to improve with the use of perioperative telemonitoring, says Kelly M. Mahuron, MD.
Treatment options in the refractory setting must improve for patients with resected colorectal cancer peritoneal metastasis, says Muhammad Talha Waheed, MD.
Karine Tawagi, MD, and Sia Daneshmand, MD, with the Oncology Brothers presenting slides
Karine Tawagi, MD, and Sia Daneshmand, MD, with the Oncology Brothers presenting slides
Karine Tawagi, MD, and Sia Daneshmand, MD, with the Oncology Brothers presenting slides
Karine Tawagi, MD, and Sia Daneshmand, MD, with the Oncology Brothers presenting slides
Although immature, overall survival data from the KEYNOTE-868 trial may support the use of pembrolizumab plus chemotherapy in patients with endometrial cancer.
Dostarlimab plus chemotherapy appears to yield favorable overall survival in patients with mismatch repair proficient endometrial cancer.
Related Content